Patisiran · ONPATTRO

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • hATTR amyloidosis with polyneuropathy
Product first approved 2019biospace.com
EU
  • Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or 2 polyneuropathy
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Other / comorbidity
NCT03997383 · Alnylam Pharmaceuticals
2019-09-04 – 2025-12-24 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
What this study did
NCT03862807 · Alnylam Pharmaceuticals
2019-03-27 – 2020-10-20 · Amyloidosis, Familial, Transthyretin Amyloidosis
What this study did
Phase 2 (2)
Other / comorbidity
NCT01961921 · Alnylam Pharmaceuticals
2013-10 – 2016-08 · TTR-mediated Amyloidosis
What this study did
NCT01617967 · Alnylam Pharmaceuticals
2012-05 – 2014-01 · TTR-mediated Amyloidosis
What this study did
Phase 1 (3)
Other / comorbidity
NCT05023889 · Austin Neuromuscular Center
2022-08-03 – 2026-04-13 · Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
What this study did
NCT02053454 · Alnylam Pharmaceuticals
2014-01 – 2014-06 · Transthyretin (TTR)-Mediated Amyloidosis
What this study did
NCT01559077 · Alnylam Pharmaceuticals
2012-03 – 2012-11 · TTR-mediated Amyloidosis
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT03759379 · Alnylam Pharmaceuticals
2019-02-14 – 2025-11-05 · Amyloidosis, Hereditary, Transthyretin Amyloidosis
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Polyneuropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Patisiran (ONPATTRO): this drugApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT01960348: Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602)
Acoramidis (Attruby)
Approved(overall)
Small moleculeTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)ApprovedRNA / oligonucleotideTransthyretin (TTR)Weak signalNo reviewed efficacy summary in this indication
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT03759379: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43)
Inotersen (Tegsedi)US approval withdrawnRNA / oligonucleotideTransthyretin (TTR)Reliable signalNo reviewed efficacy summary in this indication
Cliramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Nexiguran Ziclumeran
Phase 3(overall)
Gene therapy / editingTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2023Complete response letterFDA issues complete response letter for the patisiran sNDA in ATTR cardiomyopathy
US, FDA · Alnylam Pharmaceuticals · Source ↗